Latest news with #QTORIN™
Yahoo
04-04-2025
- Business
- Yahoo
Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
WAYNE, Pa., April 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 2:00 p.m. PT. A live webcast of the fireside chat will be available on the Events and Presentations section of Palvella's website at An archived replay of the webcast will be available for approximately 90 days following the presentation. About Palvella Therapeutics Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit or follow Palvella on LinkedIn or X (formerly known as Twitter). QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication. Contact Information InvestorsWesley H. KaupinenFounder and CEO, Palvella MediaMarcy NanusManaging Partner, Trilon Advisors, LLCmnanus@
Associated Press
04-04-2025
- Business
- Associated Press
Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
WAYNE, Pa., April 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 2:00 p.m. PT. A live webcast of the fireside chat will be available on the Events and Presentations section of Palvella's website at An archived replay of the webcast will be available for approximately 90 days following the presentation. About Palvella Therapeutics Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit or follow Palvella on LinkedIn or X (formerly known as Twitter). QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication. Wesley H. Kaupinen Media Marcy Nanus Managing Partner, Trilon Advisors, LLC
Yahoo
01-03-2025
- Business
- Yahoo
Why Palvella Therapeutics, Inc. (PVLA) is Skyrocketing So Far in 2025
We recently published an article titled . In this article, we are going to take a look at where Palvella Therapeutics, Inc. (NASDAQ:PVLA) stands against the other biotech stocks. No matter the market environment, you'll always find entertainment in the biotech space. There will always be biotech stocks making huge swings in both directions and these stocks can make or break your portfolio in a very small amount of time due to the nature of how important clinical trial results are for these companies. The United Nations forecasts that the over-65 age group will grow by 150% from 800 million in 2024 to 2 billion by 2067. This "older, richer & sicker" population is expected to push global healthcare spending on medicines up 12% to $2.3 trillion by 2028. If you combine that with AI making breakthroughs in healthcare more frequent, you'll see many more biotech stocks starting to pop to the upside over the coming years. For this article, I screened the top-performing biotech stocks year-to-date. I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A biopharmaceutical scientist in a lab examining a vial of pharmaceuticals. Number of Hedge Fund Holders In Q4 2024: 9 Palvella Therapeutics, Inc. (NASDAQ:PVLA) is a clinical-stage biopharmaceutical company that makes therapies for rare genetic skin diseases with no FDA-approved therapies. The stock is up significantly so far in 2025 after Palvella Therapeutics, Inc. (NASDAQ:PVLA)'s announcement on February 10, 2025, that it would expand its Phase 3 SELVA clinical trial of QTORIN™ rapamycin for microcystic lymphatic malformations to include younger pediatric patients aged 3 to 5 years old. Before that, Palvella Therapeutics, Inc. (NASDAQ:PVLA) announced the publication of results from its Phase 2 clinical trial of QTORIN™ rapamycin for microcystic lymphatic malformations in the Journal of Vascular Anomalies, reporting that 100% of participants were either "Much Improved" or "Very Much Improved" as rated by the Clinician Global Impression of Change. It also announced that the first patients had been dosed in its Phase 2 TOIVA clinical trial of QTORIN™ rapamycin for the treatment of cutaneous venous malformations. The consensus price target of $40.33 implies 113.97% upside. Palvella Therapeutics, Inc. (NASDAQ:PVLA) is up 56.17% year-to-date. Overall PVLA ranks 8th on our list of the biotech stocks that are skyrocketing so far in 2025. While we acknowledge the potential of PVLA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PVLA but that trades at less than 5 times its earnings, check out our report about the . READ NEXT: Why These 15 E-Commerce Stocks Are Skyrocketing So Far In 2025 and Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
